DM199 for Pregnancy Complications

Launched by DIAMEDICA THERAPEUTICS INC · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called DM199, which aims to help women with pregnancy complications like preeclampsia and fetal growth restriction (FGR). Preeclampsia is a condition that can cause high blood pressure in pregnant women and can harm both the mother and baby. DM199 has shown promise in early studies by potentially lowering blood pressure, improving blood flow in the placenta, and being safe for both mother and baby. The trial will carefully test different doses of DM199 to find the most effective amount for women experiencing these complications.

To be eligible for the trial, women must be diagnosed with preeclampsia and/or FGR, be between 27 and 42 weeks pregnant, and have a single healthy baby. They should also be admitted to the hospital for care. However, certain serious conditions, like severe preeclampsia complications or significant heart problems, may disqualify them from participating. Women who join the trial can expect to receive the new treatment while being closely monitored by healthcare professionals. This research is important as it could lead to better management of pregnancy complications and improved outcomes for mothers and their babies.

Gender

FEMALE

Eligibility criteria

• • Please refer to the Pan African Clinical Trials Registry (PACTR202404895013782).